Climb Bio, Inc.
Clinical trials sponsored by Climb Bio, Inc., explained in plain language.
-
New drug aimed at kidney disease shows promise in early trial
Disease control Recruiting nowThis phase 2 trial is testing a new drug, budoprutug (also known as TNT119), in 45 people with primary membranous nephropathy, a kidney disease that can lead to kidney failure. The study aims to see if the drug is safe and can help patients achieve remission. Participants receive…
Phase: PHASE2 • Sponsor: Climb Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New lupus drug candidate enters first human tests
Disease control Recruiting nowThis early-stage trial is testing a new drug called budoprutug (TNT119) in 30 adults with active systemic lupus erythematosus (SLE). The main goal is to check the drug's safety and how the body processes it. Participants will receive a single dose of the drug by IV, and researche…
Phase: PHASE1 • Sponsor: Climb Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New antibody drug aims to boost platelets in Hard-to-Treat ITP
Disease control Recruiting nowThis early-phase trial is testing a new drug called budoprutug (TNT119) in 24 adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, raising bleeding risk. Participants receive two IV doses and are monitored for safety, how the drug mov…
Phase: PHASE1, PHASE2 • Sponsor: Climb Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug CLYM116 enters first human safety trial
Knowledge-focused Recruiting nowThis early-stage study tests the safety of a new drug, CLYM116, in 48 healthy adults aged 18-60. Participants receive either the drug or a placebo by injection, and researchers monitor for side effects and how the drug moves through the body. The study is not designed to treat an…
Phase: PHASE1 • Sponsor: Climb Bio, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC